ATHE

Alterity Therapeutics Limited [ATHE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ATHE Stock Summary

Top 10 Correlated ETFs

ATHE

Top 10 Correlated Stocks

ATHE

In the News

ATHE Financial details

Company Rating
-
Market Cap
22.96M
Income
-9.81M
Revenue
3.56M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
30 Aug 2024
P/E
-892.09
Forward P/E
-
PEG
394.01
P/S
5.06
P/B
207.35
P/C
-
P/FCF
-1.18
Quick Ratio
5.58
Current Ratio
6.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
7.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-78.36%
Revenue last 5Y
-100%
Revenue Q/Q
6.44%
EPS Q/Q
-
-
-
-
-
SMA20
-22.81%
SMA50
-15.9%
SMA100
148.72%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-24%
ROC
-0.24%
Gross Margin
93%
Oper. Margin
-352%
Profit Margin
-337%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.55-5.41
52W High
-37.2%
52W Low
+214%
RSI
45.04
Rel Volume
0.23
Avg Volume
55.38K
Volume
12.74K
Perf Week
1.29%
Perf Month
-16.93%
Perf Quarter
161.67%
Perf Half Y
139.69%
-
-
-
-
Beta
0.765
-
-
Volatility
0.17%, 0.4%
Prev Close
9.79%
Price
3.14
Change
7.9%

Something similar

Top by Market Cap
BRH.DE
M&M.NS
AAPL
VTSAX
FXAIX
Top Correlated ETFs
PBD
HDRO.L
BBC
CTEC
HDRO
Top Correlated Stocks
NKTR
KALU
KYMR
OUKPY
LNNGY
Similar Market Cap
LYQK.DE
AIEA.L
WDFN
VRMEW
GC2U.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 55.38K
  • Market Capitalization 22.96M
  • Employee 11
  • CEO Dr. David A. Stamler M.D.
  • Headquarters Melbourne,VIC,AU
  • IPO Date 2003-09-29
  • Website https://alteritytherapeutics.com

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.